Clinical trials for Aggressive B-cell non-Hodgkin lymphoma
49 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEarly Phase 1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPhase 2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington · PI: Mengyang Di, MD, PhD
- RECRUITINGPhase 2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI) · PI: Christopher J Melani
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China · PI: Yi-jin Gao
- RECRUITINGPhase 2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China · PI: Dehui Zou
- RECRUITINGPhase 2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic · PI: Claire Tiger, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha · PI: Yazeed Sawalha
- RECRUITINGPhase 2NCT06736613A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center · PI: Jennifer Lue, MD
- RECRUITINGPhase 2NCT06534437MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)Ryvu Therapeutics SA
- RECRUITINGPhase 1NCT06544265SynKIR-310 for Relapsed/Refractory B-NHLVerismo Therapeutics · PI: Laura A Johnson, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT06242834Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaNorthwestern University · PI: Reem Karmali, MD
- RECRUITINGNCT06550427Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation SequencingNational Taiwan University Hospital · PI: Tai-Chung Huang, Ph.D
- RECRUITINGN/ANCT06485076Early Palliative Care for Patients With Multiple Myeloma and Aggressive LymphomaUniversity Health Network, Toronto · PI: Breffni Hannon, MB BCh BAO, MMedSci, MCFP
- RECRUITINGPhase 2NCT06271057Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseThe Lymphoma Academic Research Organisation · PI: Catherine THIEBLEMONT, Prof. Dr.
- RECRUITINGPhase 2NCT06461182Ga-68-CXCR4 PET/CT in Indolent B-cell LymphomaKoo Foundation Sun Yat-Sen Cancer Center
- RECRUITINGPhase 3NCT06230224A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaRegeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGPhase 2NCT06238648Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyAcademic and Community Cancer Research United · PI: Grzegorz S Nowakowski
- RECRUITINGPhase 2NCT06244368GVM±R in Patients With Relapsed or Refractory Aggressive NHL.Institute of Hematology & Blood Diseases Hospital, China · PI: Wei Liu
- RECRUITINGPhase 1NCT06180174Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaChongqing Precision Biotech Co., Ltd · PI: Yuqin Song, M.D
- ACTIVE NOT RECRUITINGPhase 2NCT06093841Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLShanghai Ming Ju Biotechnology Co., Ltd. · PI: Weili Zhao, PhD
- RECRUITINGPhase 3NCT05820841Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaUniversität des Saarlandes · PI: Konstantinos Christofyllakis, MD MSc
- RECRUITINGPHASE1, PHASE2NCT05826535Study of LYL314 in Aggressive Large B-Cell LymphomaLyell Immunopharma, Inc.
- RECRUITINGPhase 1NCT05685173A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin LymphomasRegeneron Pharmaceuticals · PI: Clinical Trial Management
- ACTIVE NOT RECRUITINGPhase 2NCT05798156Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · PI: Salah-Eddin Al-Batran, Prof. Dr.
- ACTIVE NOT RECRUITINGPhase 2NCT05583149Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasPatrick C. Johnson, MD · PI: Connor Johnson, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05270057Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesMedical College of Wisconsin · PI: Mehdi Hamadani, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05464329Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell LymphomaWashington University School of Medicine · PI: David Russler-Germain, M.D., Ph.D.
- RECRUITINGPhase 1NCT05412290Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell LymphomaWashington University School of Medicine · PI: Armin Ghobadi, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT05206357Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabGenmab · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 3NCT05171647A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaHoffmann-La Roche · PI: Clinical Trials
- ACTIVE NOT RECRUITINGPhase 1NCT05211336Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemNational Cancer Institute (NCI) · PI: Rahul Lakhotia, M.D.
- RECRUITINGPhase 2NCT05281809Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaJohn Lister · PI: John Lister, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05202782Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaNorthwestern University · PI: Reem Karmali, MD
- RECRUITINGPhase 1NCT04884035Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaCelgene · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT04531046Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell TransplantationThe Lymphoma Academic Research Organisation · PI: Roch Houot, PhD
- RECRUITINGPhase 1NCT04231877Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaUniversity of Washington · PI: Ryan Lynch
- RECRUITINGEarly Phase 1NCT04161248Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · PI: Sarit Assouline
- ACTIVE NOT RECRUITINGPhase 2NCT03964090Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)National Cancer Institute (NCI) · PI: Rahul Lakhotia, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03749018Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaDavid Bond, MD · PI: David A Bond, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03038672Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasNational Cancer Institute (NCI) · PI: Stephen M Ansell
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03625037First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaGenmab · PI: Study Official
- ACTIVE NOT RECRUITINGPhase 3NCT03206671Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsUniversity Hospital Muenster · PI: Birgit Burkhardt, Prof. Dr. Dr.
- ACTIVE NOT RECRUITINGPhase 1NCT02651662A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesRegeneron Pharmaceuticals · PI: Clinical Trial Management
- ACTIVE NOT RECRUITINGPhase 2NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · PI: Michael Crump
- ACTIVE NOT RECRUITINGNCT02633111DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin LymphomasMemorial Sloan Kettering Cancer Center · PI: Anita Kumar, MD
- RECRUITINGPhase 1NCT01853631Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)Baylor College of Medicine · PI: Carlos A Ramos, MD
- ACTIVE NOT RECRUITINGPhase 1NCT01840566High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · PI: Craig Sauter, MD
- ACTIVE NOT RECRUITINGN/ANCT01787409Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyMayo Clinic · PI: Thomas E. Witzig, MD